Klinická proteomika

Doc. RNDr. Jiří Petrák, Ph.D. — Vedoucí projektu

1. lékařská fakulta Univerzity Karlovy

O nás

Proteom představuje kompletní sadu bílkovin, které se v daný okamžik nacházejí v organismu, tkání či buňce. Proteomika usiluje o kvantitativní i kvalitativní popis proteomů a jejich fyziologických i patologických změn.

Nejmodernější proteomické postupy umožňují detekci a relativní kvantifikaci až 10 000 bílkovin v jediném experimentu a otevírají tak cestu k popisu mnohých fyziologických a patologických procesů na molekulární úrovni. Právě s pomocí proteomických nástrojů – účinných elektroforetických a chromatografických separačních metod kombinovaných s hmotnostní spektrometrií – se náš tým pokouší popisovat molekulární mechanismy závažných onemocnění a vyhledávat klinicky využitelné biomarkery.

Aktuální projekty:

Studium změn v nádorových buňkách spojených s rezistencí na chemoterapii.
Studium molekulárních procesů spojených se srdečním selháním
Vývoj nových přístupů k proteomické analýze transmembránových proteinů.

Aktuální informace o naší skupině najdete na naší stránce https://www.petraklab.cz/

Aktuality

Výzkumné centrum, jaké si fakulta zasloužila

Představujeme vědeckou skupinu doc. Jiřího Petráka

Stovky nemocí, jeden cíl

Publikace

2025

Běhounek M, Lipcseyová D, Vít O, Žáček P, Talacko P, Husková Z, Kikerlová S, Tykvartová T, Wohlfahrt P, Melenovský V, Beneš J, Petrák J. Biomarkers of RV Dysfunction in HFrEF Identified by Direct Tissue Proteomics: Extracellular Proteins Fibromodulin and Fibulin-5. Circ Heart Fail. 2025 Jan 17:e011984. doi: 10.1161/CIRCHEARTFAILURE.124.011984. Epub ahead of print. PMID: 39823288.

Daumova L, Manakov D, Petrak J, Sovilj D, Behounek M, Andera L, Vit O, Souckova O, Havranek O, Dolnikova A, Renesova N, Tuskova L, Winkowska L, Bettazova N, Kupcova K, Kalbacova MH, Sikorova M, Trneny M, Klener P. Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors. Cell Death Discov. 2025 Feb 18;11(1):65. doi: 10.1038/s41420-025-02341-y. (IF 6.1)

2024

Majtan T, Olsen T, Sokolova J, Krijt J, Křížková M, Ida T, Ditrói T, Hansikova H, Vit O, Petrak J, Kuchař L, Kruger WD, Nagy P, Akaike T, Kožich V. Deciphering pathophysiological mechanisms underlying cystathionine beta-synthase-deficient homocystinuria using targeted metabolomics, liver proteomics, sphingolipidomics and analysis of mitochondrial function. Redox Biology. 2024 volume 73; 103222, ISSN 2213-2317. https://doi.org/10.1016/j.redox.2024.103222.

Petrak J, Tevosian SG, Richter S, Ghayee HK. Metabolomics and proteomics in pheochromocytoma and paraganglioma: Translating biochemistry and biology to bedside. Best Pract Res Clin Endocrinol Metab. 2024 Sep 5:101935. doi: 10.1016/j.beem.2024.101935.

Vít O, Petrák J. Autotaxin and Lysophosphatidic Acid Signalling: the Pleiotropic Regulatory Network in Cancer. Folia Biol (Praha). 2023;69(5-6):149-162. doi:10.14712/fb2023069050149.

2023

Vit O, Talacko P, Musil Z, Hartmann I, Pacak K, Petrak J. Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization. Clin Proteom 20, 39 (2023). https://doi.org/10.1186/s12014-023-09428-7.

Benes J, Kroupova K, Kotrc M, Petrak J, Jarolim P, Novosadova V, Kautzner J, Melenovsky V. FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF. Sci Rep. 2023 Sep 25;13(1):16004. doi: 10.1038/s41598-023-42558-4. (IF 18.2)

2022

Soukup J, Kostelanská M, Kereïche S, Hujacová A, Pavelcová M, Petrák J, Kubala Havrdová E, Holada K. Flow Cytometry Analysis of Blood Large Extracellular Vesicles in Patients with Multiple Sclerosis Experiencing Relapse of the Disease. Journal of Clinical Medicine. 2022; 11(10):2832. https://doi.org/10.3390/jcm11102832.

Jankovska E, Lipcseyova D, Svrdlikova M, Pavelcova M, Kubala Havrdova E, Holada K, Petrak J. Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis. Int J Neurosci. 2022 Jul;132(7):724-734. doi: 10.1080/00207454.2020.1837801. (IF 2.590)

2021

Hrdinova T, Toman O, Dresler J, Klimentova J, Salovska B, Pajer P, Bartos O, Polivkova V, Linhartova J, Machova Polakova K, Kabickova H, Brodska B, Krijt M, Zivny J, Vyoral D, Petrak J. Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib. Int J Oncol. 2021 Feb;58(2):238-250. doi: 10.3892/ijo.2020.5163.

Havlenova T, Skaroupkova P, Miklovic M, Behounek M, Chmel M, Jarkovska D, Sviglerova J, Stengl M, Kolar M, Novotny J, Benes J, Cervenka L, Petrak J, Melenovsky V. Right versus left ventricular remodeling in heart failure due to chronic volume overload. Sci Rep. 2021 Aug 24;11(1):17136. doi: 10.1038/s41598-021-96618-8.

Vit O, Patel M, Musil Z, Hartmann I, Frysak Z, Miettinen M, Pacak K and Petrak J. Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity. Molecules 2021, 26, 6567.

2020

Jankovska E, Lipcseyova D, Svrdlikova M, Pavelcova M, Kubala Havrdova E, Holada K, Petrak J. Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis. Int J Neurosci. 2020 Oct 29:1-11. doi: 10.1080/00207454.2020.1837801. Epub ahead of print. PMID: 33059501.

2019

Petrak J, Havlenova T, Krijt M, Behounek M, Franekova J, Cervenka L, Pluhacek T, Vyoral D, Melenovsky V. Myocardial iron homeostasis and hepcidin expression in a rat model of heart failure at different levels of dietary iron intake. Biochim Biophys Acta Gen Subj. 2019 Apr;1863(4):703-713. doi: 10.1016/j.bbagen.2019.01.010.

Jankovska E, Svitek M, Holada K, Petrak J. Affinity depletion versus relative protein enrichment: a side-by-side comparison of two major strategies for increasing human cerebrospinal fluid proteome coverage. Clin Proteom (2019) 16:9 https://doi.org/10.1186/s12014-019-9229-1

Vit O, Harant K, Klener P, Man P, Petrak J. A three-pronged “Pitchfork” strategy enables an extensive description of the human membrane proteome and the identification of missing proteins. J Proteomics. 2019 Jul 30;204:103411.

2018

Melenovsky V, Hlavata K, Sedivy P, Dezortova M, Borlaug BA, Petrak J, Kautzner J, Hajek M. Skeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure. Circ Heart Fail. 2018; 11e004800. doi: 10.1161/CIRCHEARTFAILURE.117.004800.

Krijt M, Jirkovska A, Kabickova T, Melenovsky V, Petrak J, Vyoral D. Detection and quantitation of iron in ferritin, transferrin and labile iron pool (LIP) in cardiomyocytes using 55Fe and storage phosphorimaging. BBA-GEN SUBJECTS 1862 (2018) 2895-2901. https://doi.org/10.1016/j.bbagen.2018.09.005.

Melenovsky V, Cervenka L, Viklicky O, Franekova J, Havlenova T, Behounek M, Chmel M, Petrak J. Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome. Kidney Blood Press Res. 2018 Sep 20;43(5):1437-1450. doi: 10.1159/000493657.

2017

Vit O, Petrak J. Integral membrane proteins in proteomics. How to break open the black box? J Proteomics. 2017 Feb 5;153:8-20

Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J. Myocardial iron content and mitochondrial function in human heart failure: a direct tissueanalysis. Eur J Heart Fail. 2017 Apr;19(4):522-530

Vyoral D, Petrak J. Therapeutic potential of hepcidin - the master regulator of iron metabolism. Pharmacol Res. 2017 Jan; 115:242-254.

Zimmermannova O, Doktorova E, Stuchly J, Kanderova V, Kuzilkova D, Strnad H, Starkova J, Alberich-Jorda M, Falkenburg JHF, Trka J, Petrak J, Zuna J, Zaliova
M. An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia. Oncogene. 2017 Oct 26;36(43):5985-5994.

2016

Vit O, Man P, Kadek A, Hausner J, Sklenar J, Harant K, Novak P, Scigelova M,Woffendin G, Petrak J. Large-scale identification of membrane proteins based onanalysis of trypsin-protected transmembrane segments. J Proteomics. 2016 Oct 21;149:15-22

Toman O, Kabickova T, Vit O, Fiser R, Polakova KM, Zach J, Linhartova J,Vyoral D, Petrak J. Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target. Oncol Rep. 2016 Sep;36(3):1258-68.

Sedmera D, Neckar J, Benes J Jr, Pospisilova J, Petrak J, Sedlacek K,Melenovsky V. Changes in Myocardial Composition and Conduction Properties in Rat Heart Failure Model Induced by Chronic Volume Overload. Front Physiol. 2016 Aug 25;7:367.

2015

Lorkova L, Scigelova M, Arrey TN, Vit O, Pospisilova J, Doktorova E, Klanova M, Alam M, Vockova P, Maswabi B, Klener P Jr, Petrak J. Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells.. PLoS One. 2015 Aug 18;10(8):e0135314.

2014

Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Vockova P, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksa R, Hernandez F, Trneny M,Vokurka M, Petrak J, Klener P Jr. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.. Mol Cancer. 2014 Jun 27;13:159.